Welcome to MaineLifeScience.com
MaineLifeScience.com is part of a specialized network of state based biotechnology, medical device,
and life science sites that includes more than 3,500 biotechnology, medical device, pharmaceutical companies,
non-profit research institutions, universities and supporting service sector companies across the U.S.
This network addresses the growing informational and service needs of companies, patients, educators and others in
their respective states while providing clients the opportunity to cost effectively
advertise their job openings, events, facility availability and other services at the state level,
regionally or nationwide. We welcome your comments, suggestions and requests for informational content and supporting
services.
More...
|
|
Learn About Maine's BioHistory
Why is there a biotechnology industry in Maine? Will the industry continue
to grow in Maine? What do other states have? Each state has a unique story
that explains why a given industry has developed in a specific region and not in others.
Through Maine BioHistory, you can learn about the scientists,
institutions, political leaders, and significant events that have shaped and are still shaping
the biotechnology, medical device and life science industries in the state of Maine.
More ME BioHistory...
|
Local News...
Free News Release Posting & Archiving Service
- Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye Bayer HealthCare and development partner Regeneron Pharmaceuticals announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.
Bayer May 08, 2008
- AstraZeneca submits sNDA for Seroquel XR for the treatment of generalised anxiety disorder AstraZeneca announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for SEROQUEL XR(TM) Extended-Release Tablets to seek approval for the treatment of generalised anxiety disorder, including maintenance of antianxiety effect.
AstraZeneca May 08, 2008
- LFB Biotechnologies and GTC Biotherapeutics to collaborate on rhAAT program GTC Biotherapeutics and LFB Biotechnologies have agreed to include GTC's recombinant human alpha-1 antitrypsin program in their strategic collaboration for the development of selected recombinant plasma proteins and monoclonal antibodies.
GTC Biotherapeutics, Inc. May 08, 2008
- Caliper Life Sciences reports first quarter 2008 results Caliper Life Sciences reported its first quarter financial results for 2008. First quarter revenues were $29.3 million, an increase of 3% over revenues of $28.4 million in the same period in 2007.
Caliper Life Sciences, Inc. May 08, 2008
- GTC Biotherapeutics reports first quarter 2008 financial results GTC Biotherapeutics net loss for the first quarter of 2008 was $8.2 million, or $0.10 per share, compared with $7.5 million, or $0.10 per share, in the first quarter of 2007.
GTC Biotherapeutics, Inc. May 08, 2008
More... | Submit News Release | National News
|